Objective To investigate the impact of persistent inflammation in hemodialysis (HD) patients on the pharmacokinetics of alprazolam, a cytochrome P450 (CYP) 3A4 substrate, and its metabolites and the role of HD in the impact of persistent inflammation in this clinical context. Methods The study population comprised 26 HD patients (mean age 64 years, range 27-79 years; 19 men, 7 women) who were given 1 mg of alprazolam orally in the evening before the day of HD. Unconjugated and conjugated alprazolam and its 4-hydroxy and α-hydroxy metabolites were measured by liquid chromatography-mass spectrometry at 10, 34 (start of HD) and 38 (end of HD) h after intake. C-reactive protein (CRP) was measured weekly beginning 2 months before study initiation, and alpha 1-acid glycoprotein and 4β-hydroxycholesterol were measured at baseline. CYP3A4 activity was estimated as the ratio of unconjugated alprazolam to 4-hydroxyalprazolam between 10 and 34 h following alprazolam intake.
Introduction
Cytochrome P450 3A4 (CYP3A4), a member of the CYP group of drug-metabolising enzymes, is involved in the metabolism of almost 50% of all currently prescribed drugs. Any alteration in the activity of this enzyme may change the plasma concentrations of the drugs that it metabolises and consequently alter the clinical effect. During recent years, data across different disciplines have accumulating on the impact of inflammation on drug metabolism [1] . In a recent review, Morgan discusses the possible downregulation of multiple P450 enzymes as well as other drug-metabolising enzymes and transporters by inflammation associated with infections or other disease states [1] . Further important points raised in that review are that not only hepatic but also the intestinal CYP3A4 might be downregulated by inflammation [2] and that the pattern of regulation of drug metabolism differs depending on the disease. For example, serum interleukin-6 concentrations correlate with the reduced CYP3A4-dependent drug clearance in cancer patients [1, 3, 4] . Few clinical studies on the impact of inflammation on drug metabolism have been conducted, but several interesting studies have been performed on animals [5] . These animal studies have shown that downregulation of P450 isozymes and P-glycoprotein occurs at the gene transcription level through the mediation of the cytokines. Posttranslational steps have also been implicated in this process. Several experimental animal studies has shown that different types of infection (bacterial, viral or parasitic) can downregulate the activity and/expression of drug-metabolising enzymes in the liver. These effects can also be mimicked by sterile inflammatory agents. One of the best examples is bacterial lipopolysaccharide, which can downregulate multiple P450 mRNAs in the liver [5] .
As the kidney is an important organ of drug disposition through its excretion of the parent drugs and their metabolites, patients with chronic kidney disease (CKD) have difficulty eliminating many drugs. CKD and the uremic milieu can differentially affect the metabolic enzymes and the uptake and efflux transporters in the liver and gastrointestinal tract [6] . Persistent low-grade inflammation is a common finding in patients with CKD [7] .
In the study presented here, we investigated the impact of inflammation, expressed as the level of high-sensitivity C-reactive protein (hsCRP) and/or alpha 1-acid glycoprotein, on drug metabolism in prevalent hemodialysis (HD) patients using alprazolam as a test drug. Alprazolam is metabolised by CYP3A4 to both 4-hydroxyalprazolam and α-hydroxyalprazolam, which in turn are conjugated to more water-soluble metabolites. The kidney normally excretes these conjugated metabolites, but in CKD the excretion of such metabolites is decreased [8, 9] . The metabolic pathways for alprazolam are shown in Fig. 1 . In early studies, 4-hydroxyalprazolam was found to be mainly produced by CYP3A4 and α-hydroxyalprazolam by CYP3A5 [10] [11] [12] ; Allqvist et al. [13] , however, subsequently demonstrated that both metabolites are mainly formed by CYP3A4 and that the role of CYP3A5 is insignificant. Based on this finding, alprazolam can be used as probe drug only for CYP3A4 [13] .
Patients and methods
This study was performed at the Karolinska University Hospital, Huddinge, Sweden and its satellite HD units in the Stockholm area. The Ethics Committee of Karolinska Institutet, Huddinge approved the study. Twenty-seven prevalent HD patients agreed to participate in the study, and all participants gave their written informed consent on the basis of the verbal and written information they had received. Results from one patient were not included in the final calculations due to missing data. The general characteristics of the remaining 26 patients participating in this pharmacokinetic study are presented in Table 1 . All of the patients had three HD sessions per week (3.5-5 h/session) using low-flux polysolphone membrane dialysers.
Each patient was given 1 mg alprazolam (Xanor, 1 mg; Pfizer, New York, NY) orally in the evening before the day of dialysis (as previously described in healthy subjects) [13] . None of the patients were being treated with CYP3A4 inhibitors or inducers. Peripheral blood samples (10 ml) were collected into EDTA-containing tubes at 10, 34 (start of HD) and 38 (end of HD) h after alprazolam intake. The plasma was separated and stored frozen at -20°C until analysed. The concentrations of conjugated and unconjugated alprazolam and its metabolites α-and 4-hydroxyalprazolam were quantified in plasma by liquid chromatography-mass spec- Fig. 1 Metabolic pathways for alprazolam. CYP3A5 has no major role in the disposition of alprazolam [13] . CYP3A4 Cytochrome P450 3A4 trometry as described by Allqvist et al. [14] . Total concentrations (unconjugated + conjugated) of alprazolam and its metabolites were determined after hydrolysis with β-glucuronidase (from Escherichia coli K12; Roche, Basel, Switzerland). In brief, 400 μl of plasma was mixed with 100 μl β-glucuronidase solution (prepared by mixing 1.5 ml β-glucuronidase with 5 ml of 1.0 M potassium phosphate buffer pH 6.0) and incubated at 37°C for 15 min. The hydrolysed compounds were quantitated as described previously for unconjugated alprazolam and metabolites [14] . All samples from each patient were analysed in duplicate, and the average of these two values was calculated. The area under the curve (AUC) and half-life (t ½ ) were calculated for alprazolam and its metabolites using the 10-and 34-h concentrations on a semi-logarithmic graph. The 0-h concentration could also be extrapolated from this graph. CYP3A4 activity was estimated as the ratio of unconjugated alprazolam to 4-hydroxyalprazolam and expressed as AUC 10-34h . The basal (baseline) level of alpha 1-acid glycoprotein was measured, and the hsCRP level was measured weekly during the 8 weeks prior to the intake of the test drug to estimate the degree of inflammation. The median value for the last five hsCRP measurements was calculated. Plasma alpha 1-acid glycoprotein, cholesterol and hsCRP levels were measured by validated routine methods used by the accredited clinical chemistry laboratory at Karolinska University Hospital, Huddinge. Plasma 4β-hydroxycholesterol was analysed according to Bodin et al. [15] .
Statistical methods
All variables were expressed as the mean±standard deviation (SD), median (range) or percentage, unless otherwise indicated. Statistical significance was set at the level of P<0.05.
Correlations between two groups of values were assessed using the nonparametric Spearman rank's test or paired student t test. Analyses were performed using the Prism 5 sofware program (GraphPad Software, San Diego, CA).
Results
After a single dose of alprazolam, the plasma concentrations of unconjugated alprazolam and metabolites decreased in all patients, and HD seemed to have no or only a minor effect on their plasma levels ( Fig. 2, left) . However, the metabolic ratio (MR) of unconjugated alprazolam to 4-hydroxyalprazolam changed significantly from 34 to 38 h after drug administration (P<0.0001), indicating that HD had a significant effect even on the unconjugated compounds (Fig. 3) . The MR decreased from 10 to 34 h after drug administration and the curve was more steep (10/34 h: 55±43) in our patients than in healthy individuals [16] . The average t ½ for alprazolam in our 26 patients was 17 h (median 15.5 h, range 5-42 h), which is slightly longer compared to the 12 h that has been reported in normal individuals [17] . There was an almost 40-fold interindividual variation in the concentration of unconjugated alprazolam at 38 h, i.e. after HD (0.97-36 nM). For unconjugated 4-hydroxyalprazolam and α-hydroxyalprazolam, the interindividual differences in the concentrations were about tenfold (Fig. 2, left) . The interindividual variation in extrapolated 0-h concentrations of unconjugated alprazolam was smaller than the variation in the 34-h concentration, indicating that there was no substantial variation in the drug absorption or first-pass metabolism among our patients. It was possible to measure the conjugated alprazolam in all patients. In healthy individuals, this metabolite is normally cleared very rapidly from plasma via the kidneys, but it remained unchanged in our study patients, who had little/no kidney function, until HD (Fig. 2, right) . To the best of our knowledge, this is the first time that conjugated alprazolam has been measured in human plasma. The concentration of conjugated alprazolam was similar to that of conjugated hydroxy metabolites (Fig. 2, right) , and the concentrations of both conjugated alprazolam and its metabolites remained unchanged and even increased from 10 to 34 h after drug administration, i.e. the start of the HD session. During the HD session, their concentrations decreased dramatically (Fig. 2, right) , with the mean concentration of conjugated alprazolam decreasing by almost 80% (P<0.0001), and the mean concentrations of conjugated 4-hydroxyalprazolam and α-hydroxyalprazolam decreasing by 75 (P<0.0001) and 68% (P<0.0001), respectively. CYP3A4 activity, determined as the ratio of unconjugated AUC alprazolam to AUC 4-hydroxyalpazolam (MR) during the 10-34 h following drug administration, was significantly correlated (r s =0.49, P=0.011, n=26) to the degree of inflammation (expressed as the median CRP of the last 5 weeks of the study) (Fig. 4) . This result shows that patients with a higher CRP level had a higher ratio of unconjugated AUC alprazolam to AUC 4-hydroxyalpazolam, indicating lower activity of CYP3A4. Similarly, there was a significant correlation between the t ½ of unconjugated alprazolam and median CRP level (r s =0.39, P=0.047). We also found a significant correlation between the MR of alprazolam and the last measured CRP value (P=0.029). The ratio of unconjugated AUC alprazolam to AUC unconjugated α-hydroxyalprazolam showed, however, no significant correlation with CRP (r s =0.03, P=0.89), The ratio of AUC unconjugated alprazolam to total 4-hydroxyalprazolam (conjugated + unconjugated) was significantly correlated to the CRP value (r s =0.47, P=0.016), but the total α-hydroxyalprazolam was not (r s =0.19, P=0.35).
The ratio of 4β-hydroxycholesterol to cholesterol, which is an endogenous marker for CYP3A4 [18] , was not significantly correlated to the median CRP value (P=0.87) in our group of patients. Alpha 1-acid glycoprotein (another marker for inflammation) and CYP3A4 activity were not significantly correlated to either alprazolam MR or 4β-hydroxycholesterol/cholesterol. No major side effect was reported during the study.
Discussion
As early as 1977, increased plasma protein binding of propranolol and chlorpromazine was shown to be mediated by disease-induced elevations of plasma alpha 1-acid glycoprotein, an acute-phase plasma protein [19] . Several studies in recent years have shown that the expression of drug-metabolising enzymes (DME) and transporters is downregulated by inflammation [1, 3, [20] [21] [22] . Chronic inflammation in patients with cancer may cause similar changes in DMEs and transporters [3] . A link between tumor-derived cytokines and the downregulation of CYP3A4 has been shown in tumor-bearing mice [3] .
HD patients represent a sensitive group of patients, and many have multiple complications, making it difficult to participate in studies that include tests that are not included in their normal dialysis routine. Consequently, for ethical reasons we did not include more than three measurement moments in the design of our study. The patients only had to come to the hospital to leave the 10-h blood sample in addition to the routine visit the next day for HD as planned.
The increasing concentration of conjugated alprazolam and its metabolites from 10 to 34 h following the administration of alprazolam (Fig. 2, right) may be explained by the decreased kidney function of our patients, since conjugated compounds are very slowly eliminated by the kidneys of CKD patients. Newly conjugated compounds will be added to the conjugated alprazolam and metabolites already accumulating in the plasma and thereby still further increase their plasma concentration. Another possible explanation may be enterohepatic recirculation. The alprazolam conjugates reach the intestine via bile secretion and are subsequently hydrolysed to unconjugated compounds. They will then be reabsorbed from the intestine and reach the blood circulation. These unconjugated compounds can again be glucuronidated and be present in the plasma as conjugated alprazolam or metabolites. Such an extrahepatic recirculation would then prolong the elimination of the unconjugated compounds, resulting in their increased concentrations in plasma, which is indicated by the higher ratio for alprazolasm and its metabolites (Fig. 3) . This in turn could result in the slightly higher t ½ in these patients compared to healthy subjects (see above). Figure 3 shows a steep decrease in the MR of unconjugated alprazolam to unconjugated 4-hydroxyalprazolam from 10 to 34 h after drug administration, which is more rapid than that in healthy individuals [16] . The MR increased during dialysis, indicating that HD had a significant effect even on unconjugated alprazolam and/or unconjugated 4-hydroxyalprazolam (Fig. 3) .
One possible explanation for the increased MR during HD (Fig. 3) could be that 4-hydroxyalprazolam is more polar than alprazolam and therefore should be eliminated more rapidly during HD. Alternatively, alprazolam may have a longer t ½ than 4-hydroxyalprazolam due to enterohepatic recirculation of alprazolam. There was a significant correlation between CRP and ratio for alprazolam and its major metabolite 4-hydroxyalprazolam [16] , indicating that inflammation could reduce the activity of CYP3A4 (Fig. 4) . There was no significant correlation between CRP and the metabolic ratio of alprazolam and its other metabolite, α-hydroxyalprazolam. This could possibly be explained by the low concentrations of this metabolite and thereby more variability in the measurement of this α-hydroxy metabolite.
There was no significant correlation between the metabolic ratio of alprazolam and the second surrogate marker of inflammation, alpha 1-acid glycoprotein. One explanation may be that whereas CRP was used as a median value, calculated from the weekly measurements taken during the 5 weeks preceding drug intake, alpha 1-acid glycoprotein was measured only once at baseline. Based on data collected before and at the time of drug intake, none of our patients had very high CRP levels, an indication of acute infectious processes. An important point is that we could demonstrate that even a relatively low degree of inflammation could reduce CYP3A4 activity. Further studies are needed to demonstrate if a higher degree of inflammation would reduce CYP3A4 activity even more.
The AUC ratio of unconjugated alprazolam to unconjugated 4-hydroxyalprazolam might be a more suitable marker for CYP3A4 activity than the ratio of 4β-hydroxycholesterol to cholesterol or 4β-hydroxycholesterol itself in our group of patients. 4β-Hydroxycholesterol is a useful marker for determining CYP3A4 activity in healthy individuals [23] and for detecting the induction of this enzyme [24] . This cholesterol metabolite is, however, very slowly eliminated after induction [25] . If the degree of inflammation in our patients were to vary over time, this variation may not be reflected by changes in the metabolism of the slowly eliminated 4β-hydroxycholesterol.
The rate of mortality is high among CKD patients [26] , with cardiovascular disease (CVD) being the most common cause of mortality among this patient population. The high rate of CVD cannot be adequately explained by traditional risk factors, such as hypertension, dyslipidemia and smoking alone [7, 27] ; rather, non-traditional risk factors, such as inflammation and oxidative stress, seem to be more important in this group of patients [7, 28, 29] . Several studies have shown an association between increased mortality and elevated CRP in both HD and peritoneal dialysis (PD) patients [30] . Inflammation has been shown to be a strong predictor of the number of atherosclerotic plaques in the carotid arteries of end stage renal disease patients, and a strong association has been found between the level of atherosclerosis and elevated CRP [31] . In addition, the results reported here also shown that inflammation may also play an important role in drug metabolism.
The clinical consequence of reduced CYP3A4 activity is an increased plasma drug concentration at a certain dose. CKD and the uremic state itself could also alter the activity of some CYP enzymes [6] , which would in turn have an additive effect on drug metabolism and possibly increase the risks for drug accumulation and concentrationdependent adverse drug reactions. This is also the risk associated with the decreased renal excretion of drugs. We cannot exclude the possibility that alprazolam glucuronides have some clinical effects, as previous studies have shown that some glucuronides (e.g. morphine glucuronides) have important clinical effects [8, 9] .
Another interesting finding of our study is that conjugated alprazolam can be quantitated in human plasma. To the best of our knowledge, this is the first report of conjugated alprazolam being measured in human plasma; in healthy individuals, this metabolite is normally excreted very rapidly from the plasma. This finding indicates that the renal clearance of this drug metabolite was reduced in our HD patients. At the present time, it is not known if conjugated alprazolam is active. In a previous study, however, we did demonstrate that the polar and active metabolite morphine-6-glucuronate could accumulate in dialysis patients [9] .
Conclusion
The renal elimination (excretion) of some drugs and metabolites is decreased in HD patients, but the rate of drug metabolism might also be decreased in these patients due to inflammation. Our study shows that even a low degree of inflammation (expressed as increased median CRP) can significantly reduce CYP3A4 activity. In all of the patients enrolled in our study, the conjugated metabolites remained at high levels until HD, which reduced the concentrations of conjugated alprazolam and metabolites. However, the level of unconjugated compounds also seemed to be affected by HD, as indicated by significant changes in the metabolic ratio of unconjugated alprazolam to 4-hydroxyalprazolam. Larger studies are needed to investigate if more severe inflammation has more profound effects on drug metabolism in this patient group as well as other persistently inflamed patients.
